A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers.
gene expression signature
prognosis
triple negative breast cancer
tyrosine kinase
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Aug 2019
13 Aug 2019
Historique:
received:
15
07
2019
revised:
04
08
2019
accepted:
09
08
2019
entrez:
16
8
2019
pubmed:
16
8
2019
medline:
16
8
2019
Statut:
epublish
Résumé
Triple negative breast cancer (TNBC) represent 15% of breast cancers. Histoclinical features and marketed prognostic gene expression signatures (GES) failed to identify good- and poor-prognosis patients. Tyrosine kinases (TK) represent potential prognostic and/or therapeutic targets for TNBC. We sought to define a prognostic TK GES in a large series of TNBC. mRNA expression and histoclinical data of 6379 early BCs were collected from 16 datasets. We searched for a TK-based GES associated with disease-free survival (DFS) and tested its robustness in an independent validation set. A total of 1226 samples were TNBC. In the learning set of samples (N = 825), we identified a 13-TK GES associated with DFS. This GES was associated with cell proliferation and immune response. In multivariate analysis, it outperformed the previously published GESs and classical prognostic factors in the validation set (N = 401), in which the patients classified as "low-risk" had a 73% 5-year DFS versus 53% for "high-risk" patients
Identifiants
pubmed: 31412533
pii: cancers11081158
doi: 10.3390/cancers11081158
pmc: PMC6721506
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ligue Contre le Cancer
ID : EL2016
Références
Sci Rep. 2017 Nov 3;7(1):14976
pubmed: 29101386
Cancer Res. 2006 May 1;66(9):4636-44
pubmed: 16651414
J Biol Chem. 2002 Apr 19;277(16):14153-8
pubmed: 11809760
Biostatistics. 2003 Apr;4(2):249-64
pubmed: 12925520
Cancer Genomics Proteomics. 2014 Sep-Oct;11(5):239-49
pubmed: 25331796
Oncotarget. 2017 May 13;8(43):73705-73722
pubmed: 29088738
Cancer Res. 2017 Jan 1;77(1):86-99
pubmed: 27793840
Cancer Res Treat. 2009 Sep;41(3):117-21
pubmed: 19809560
Mol Cancer. 2011 Jul 21;10:86
pubmed: 21777462
Int J Cancer. 2008 Jul 1;123(1):236-40
pubmed: 18398844
N Engl J Med. 2004 Dec 30;351(27):2817-26
pubmed: 15591335
Science. 2002 Dec 6;298(5600):1912-34
pubmed: 12471243
Cancer Biol Ther. 2009 Aug;8(16):1550-8
pubmed: 19830888
Br J Cancer. 2012 Mar 13;106(6):1187-95
pubmed: 22353809
Cancer Res. 2008 Feb 1;68(3):767-76
pubmed: 18245477
Mod Pathol. 2009 Jan;22(1):151-60
pubmed: 19011600
Int J Mol Sci. 2018 Nov 06;19(11):
pubmed: 30404198
Clin Cancer Res. 2009 Oct 15;15(20):6327-40
pubmed: 19808870
J Clin Invest. 2019 Mar 1;129(3):1329-1344
pubmed: 30645202
J Natl Cancer Inst. 2005 Aug 17;97(16):1180-4
pubmed: 16106022
Breast Cancer Res. 2015 Sep 17;17:127
pubmed: 26384210
Curr Oncol Rep. 2017 Aug 10;19(10):64
pubmed: 28799073
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2824-8
pubmed: 19196983
BMC Cancer. 2018 Apr 27;18(1):473
pubmed: 29699511
Science. 2010 Feb 26;327(5969):1098-102
pubmed: 20185720
J Med Chem. 2018 Jun 28;61(12):5073-5092
pubmed: 29266937
Genes Chromosomes Cancer. 1993 Aug;7(4):219-26
pubmed: 7692948
PLoS One. 2016 Jun 16;11(6):e0157368
pubmed: 27310713
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Br J Cancer. 2009 Apr 7;100(7):1095-102
pubmed: 19277044
Breast Cancer Res. 2009;11(2):R15
pubmed: 19272155
Eur J Surg Oncol. 2007 Apr;33(3):294-300
pubmed: 17129704
Biochem Cell Biol. 2011 Apr;89(2):115-29
pubmed: 21455264
J Clin Oncol. 2009 Mar 10;27(8):1160-7
pubmed: 19204204
Ann Oncol. 2008 Aug;19(8):1379-1386
pubmed: 18487549
Cold Spring Harb Perspect Biol. 2013 Sep 01;5(9):
pubmed: 24003208
Oncologist. 2013;18(9):1060-1
pubmed: 23960187
N Engl J Med. 2010 Nov 11;363(20):1938-48
pubmed: 21067385
Stat Med. 1990 Jul;9(7):811-8
pubmed: 2218183
Springerplus. 2013 Oct 01;2:497
pubmed: 24102046
BMC Genomics. 2006 May 16;7:115
pubmed: 16704732
Cancers (Basel). 2019 Apr 17;11(4):
pubmed: 30999598
Nat Rev Mol Cell Biol. 2005 Jun;6(6):462-75
pubmed: 15928710
Acta Oncol. 2018 Jan;57(1):74-82
pubmed: 29168430
PLoS One. 2017 Jan 31;12(1):e0171169
pubmed: 28141839
Nat Med. 2015 Jul;21(7):751-9
pubmed: 26099045
PLoS One. 2017 Aug 18;12(8):e0182705
pubmed: 28820908
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
Cancer Res. 2010 Nov 15;70(22):9391-401
pubmed: 20861192
Proc Natl Acad Sci U S A. 2010 Apr 13;107(15):6994-9
pubmed: 20335537
Cancer Lett. 2018 Oct 10;434:160-171
pubmed: 30055288
Genome Biol. 2007;8(8):R157
pubmed: 17683518
PLoS Comput Biol. 2011 Oct;7(10):e1002240
pubmed: 22028643
Cold Spring Harb Perspect Biol. 2010 Jul;2(7):a002287
pubmed: 20519342
Eur J Cancer. 2017 Oct;84:34-43
pubmed: 28780480
J Clin Oncol. 2018 Apr 1;36(10):1020-1044
pubmed: 29380678
Curr Cancer Drug Targets. 2015;15(8):739-49
pubmed: 26452386
Nat Rev Cancer. 2004 Jun;4(6):470-80
pubmed: 15170449
Br J Cancer. 2018 Nov;119(11):1383-1391
pubmed: 30353048
N Engl J Med. 2002 Dec 19;347(25):1999-2009
pubmed: 12490681
Nat Med. 2018 May;24(4):505-511
pubmed: 29578538
Stat Appl Genet Mol Biol. 2004;3:Article3
pubmed: 16646809
J Clin Oncol. 2010 Apr 10;28(11):1813-20
pubmed: 20231686
Oncogene. 2018 Oct;37(42):5682-5693
pubmed: 29970903
Oncologist. 2013;18(2):123-33
pubmed: 23404817
Clin Cancer Res. 2019 Aug 15;25(16):5002-5014
pubmed: 30837276
Anticancer Res. 2016 Mar;36(3):1211-9
pubmed: 26977017
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Cell. 2012 Apr 13;149(2):307-21
pubmed: 22500798